title: Modulation of the BCL-2/BAX ratio by interferon-gamma and hypoxia in human peritoneal and adhesion fibroblasts.
abstract: OBJECTIVE
  To examine the effect of interferon (IFN)-gamma treatment under normal and hypoxic conditions on the BCL-2/BAX ratio of fibroblasts obtained from normal peritoneal and adhesion tissues of the same patients.
  
  
  METHODS
  Prospective experimental study.
  
  
  METHODS
  University medical center.
  
  
  METHODS
  Fibroblasts from peritoneum and adhesion tissues of 5 patients.
  
  
  METHODS
  Hypoxia and IFN-gamma treatments of fibroblasts.
  
  
  METHODS
  We used the multiplex polymerase chain reaction technique to measure expression of BCL-2 and BAX in normal peritoneal and adhesion fibroblasts exposed to hypoxia (2% O(2)), in the presence or absence of IFN-gamma for different time points and dosages.
  
  
  RESULTS
  At baseline, adhesion fibroblasts manifested decreased basal levels of apoptosis compared with normal fibroblasts. Hypoxia treatment resulted in a time-response decrease in apoptosis in both cell lines. Interferon-gamma treatment resulted in a dose-response increase in apoptosis in both cell lines. Hypoxia had a reduced or no effect on apoptosis in the presence of increasing doses of IFN-gamma in both cell types.
  
  
  CONCLUSIONS
  Interferon-gamma can block the effects of hypoxia on apoptosis, supporting the antifibrogenic nature of this cytokine. This suggests that IFN-gamma would be a good candidate for consideration for intervention in the development of peritoneal adhesions and fibrosis.
authors: Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, CS Mott Center for Human Growth and Development, Wayne State University, Detroit, Michigan 48201, USA.
authors: Ghassan M
authors: GM
authors: Saed
authors: Zhongliang
authors: Z
authors: Jiang
authors: Nicole M
authors: NM
authors: Fletcher
authors: Michael P
authors: MP
authors: Diamond
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D015687:Cell Hypoxia; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism* / Q000494:pharmacology; D010532:Peritoneal Diseases / Q000378:metabolism* / Q000473:pathology; D010537:Peritoneum / Q000378:metabolism* / Q000473:pathology; D011446:Prospective Studies; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D013997:Time Factors; D000267:Tissue Adhesions; D051028:bcl-2-Associated X Protein / Q000235:genetics / Q000378:metabolism*
chemical_list: C494826:BAX protein, human; D019253:Proto-Oncogene Proteins c-bcl-2; D012333:RNA, Messenger; D051028:bcl-2-Associated X Protein; D007371:Interferon-gamma